/Shanghai Ailes Pharmaceutical Technology Co., Ltd. 2025 Annual Shareholders Meeting Materials

NEWS

Shanghai Ailes Pharmaceutical Technology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Shanghai Stock Exchange

2026/04/30

Materials of the Annual Shareholders Meeting of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

2025

2 May 2026

2. The meeting will review and vote on resolutions in the order listed in the meeting notice.

Shareholders and their agents shall enjoy the right to speak, question, vote and other rights when participating in the shareholders' meeting in accordance with the law. Shareholders and shareholders' agents participating in the shareholders' meeting shall conscientiously perform their legal obligations and shall not infringe upon the legitimate rights and interests of the company and other shareholders and shareholders' agents, or disrupt the normal order of the shareholders' meeting.
Shareholders and shareholders' agents who request to speak at the on-site shareholders' meeting must register in advance. Shareholders are asked to raise their hands if they want to ask questions on the spot. They can only speak with permission from the host of the meeting. Questions from shareholders and agents should focus on the topics of this meeting, be concise and to the point, and last no more than 5 minutes. When shareholders and shareholders' agents request to speak or ask questions, they shall not interrupt the meeting reporter's report or the speeches of other shareholders and shareholder agents. Anyone who violates the above provisions may be refused or stopped by the meeting host.
The host of the meeting has the right to temporarily adjourn the meeting according to the meeting process and time schedule. The presiding officer may also adjourn the meeting when he deems it necessary.
The meeting host may arrange for company directors, senior managers, etc. to answer questions raised by shareholders. The host or his/her designated relevant personnel have the right to refuse to answer questions that may reveal the company's trade secrets, involve inside information, or harm the interests of the company/shareholders.
Shareholders and shareholders' agents attending the shareholders' meeting, unless they need to avoid voting, should express one of the following opinions on the proposals submitted for voting: agree, oppose or abstain. Shareholders present on site are required to sign their names on the voting ballot. Votes that are not filled in, filled in incorrectly, with illegible handwriting, or uncast votes will be regarded as the voter giving up the right to vote, and the voting results of the shares held by him will be counted as "abstention".
Before the voting at this on-site shareholders meeting, two shareholders will be elected to count and supervise the votes. If the matters under consideration are related to shareholders, relevant shareholders and agents are not allowed to participate in the counting and supervision of votes. When the shareholders' meeting votes on a proposal, the witness lawyer and the shareholder's agent are jointly responsible for counting and supervising the votes. The on-site voting results are announced by the meeting host. The voting results of the shareholders' meeting resolutions are recorded in the meeting minutes, and the voting results are signed by the shareholders' agents and witnessing lawyers who participated in the counting and supervision of the votes.
This meeting will be witnessed on-site by a practicing lawyer from a law firm hired by the company and a legal opinion will be issued.
This shareholders’ meeting will vote through a combination of on-site voting and online voting. An announcement on the resolutions of the shareholders’ meeting will be issued based on the results of on-site voting and online voting.
In order to ensure the solemnity and normal order of the shareholders' meeting, the company has the right to refuse entry to the venue in accordance with the law, except for shareholders and shareholders' agents present at the meeting, company directors, senior executives, retained lawyers and persons invited by the board of directors.
During the meeting, participants should pay attention to maintaining the order of the venue, do not move around at will, and set their mobile phones to silent mode. Personal audio recording, video recording and taking photos are not allowed during the meeting. Participants should not leave the venue after the meeting without special reasons. Meeting staff have the right to stop any behavior that interferes with the normal proceedings of the meeting, provokes trouble or infringes upon the legitimate rights and interests of other shareholders, and reports to the relevant departments for handling.
The expenses incurred by shareholders and their agents to attend this shareholders' meeting shall be borne by the shareholders themselves. The company will not issue gifts to shareholders who attend the shareholders' meeting, nor is it responsible for arranging accommodation and other matters for shareholders who attend the shareholders' meeting, in order to treat all shareholders equally.
For the specific content of the registration method and voting method of this shareholders' meeting, please refer to the "Notice of Shanghai Ellis Medical Technology Co., Ltd. on convening the 2025 Annual Shareholders' Meeting" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 23, 2026.

2025 Annual Shareholders Meeting Agenda

1. Meeting time, location and voting method

On-site meeting time: 14:00 on May 13, 2026
On-site meeting location: Company Conference Room, No. 268, Lingxiaohua Road, Zhoupu Town, Pudong New District, Shanghai
Meeting convener: Company Board of Directors
Moderator: Chairman Mr. Du Jinhao
Online voting system, start and end dates and voting time

Online voting system: Shanghai Stock Exchange Shareholders Meeting online voting system

Online voting start and end dates: From May 13, 2026 to May 13, 2026, the Shanghai Stock Exchange online voting system will be used. The voting time through the trading system voting platform will be the trading time period on the day of the shareholders’ meeting, that is, 9:15-9:25, 9:30-11:30, 13:00-15:00; the voting time through the Internet voting platform will be 9:15-15:00 on the day of the shareholders’ meeting.

2. Meeting Agenda

(1) Sign-in of participants, registration and confirmation of shareholder speeches (if any)

(2) The host announces the start of the meeting

(3) The host announces the attendance of the on-site meeting

(4) Read out the meeting instructions

(5) Election of scrutineers and counters

(6) Review each proposal item by item, and listen to the "2025 Independent Directors' Performance Report" and the 2026 annual remuneration plan for the company's senior managers

(7) In response to the resolutions reviewed at the meeting, shareholders made speeches and asked questions, and the company’s directors and senior managers answered shareholders’ questions

(8) Shareholders attending the meeting vote on various proposals

(9) Adjourn the meeting and count on-site voting results

(10) When the meeting resumes, the moderator announces the voting results and online voting results (the final voting results are subject to the company’s announcement)

(11) Witness the lawyer reading out the legal opinion

(12) Signing meeting documents

(13) The host announces the end of the meeting

Shanghai Ailes Pharmaceutical Technology Co., Ltd.

2025 Annual Shareholders Meeting Proposal

Proposal 1:

Proposal regarding the company's "2025 Board of Directors Work Report" Dear shareholders and shareholders' agents:

The company's "2025 Board of Directors Work Report" is detailed in Appendix 1, please review it.

The proposal has been reviewed and approved at the third meeting of the company's third board of directors and is now submitted to shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Attachment 1 of May 13, 2026:

Shanghai Ailes Pharmaceutical Technology Co., Ltd.

2025 Annual Board of Directors Work Report

In 2025, the company's board of directors will strictly abide by the "Company Law", "Securities Law", "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and other laws and regulations as well as the relevant provisions of the "Articles of Association", faithfully perform the responsibilities assigned by the company and all shareholders, actively implement various resolutions of the shareholders' meeting, and efficiently promote the work of the board of directors, providing a solid guarantee for the company's stable operation and sustainable development. The work of the Board of Directors in 2025 is now reported as follows:

1. Overall operating situation of the company in 2025

In 2025, under the strategic guidance of the board of directors, all employees of the company will closely focus on the annual operating goals and solidly promote the process of R&D innovation and commercial development. The company's core competitiveness for sustainable development will be further consolidated and enhanced. With the joint efforts of all employees, the company's operating performance has once again achieved significant improvement, laying a solid foundation for stable and long-term development.

During the reporting period, the company achieved total operating revenue of 5,187.3381 million yuan, a year-on-year increase of 45.80%, mainly due to product sales revenue of 5,160.491 million yuan from anti-tumor drugs during the reporting period. During the reporting period, the company achieved net profit attributable to owners of the parent company of RMB 2,189.105 million, a year-on-year increase of 53.10%; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was RMB 2,021.5157 million, a year-on-year increase of 48.54%.

2. Daily work of the company’s board of directors in 2025

During the reporting period, in order to further improve the operating efficiency and scientific decision-making level of the board of directors, the company adjusted the number of seats on the board of directors to 9 (including 1 employee representative director). All directors perform their duties diligently and diligently, pay close attention to the company's operations and other major matters, fully safeguard the rights and interests of small and medium-sized shareholders, and ensure the company's sustained, stable and healthy development of operations. In 2025, the operation of the company’s board of directors is as follows:

(1) Operation of the board of directors

In 2025, the board of directors mainly reviewed and approved the following matters:

Meeting date Meeting session Matters to be considered

2025/4/22 The 10th meeting of the second session of the Board of Directors "Proposal on the Company's 2024 Annual Report and its Summary"

four meetings

"Proposal on the Company's <2025 First Quarter Report>"

"Proposal on the Company's 2024 Board of Directors Work Report"

"Proposal on the Company's 2024 General Manager Work Report"

"Proposal on the Company's 2024 Financial Final Accounts Report"

"Proposal on the Company's 2024 Duty Performance Report of the Audit Committee of the Board of Directors"

"Proposal on the Company's 2024 Independent Directors' Work Report"

"Proposal on the Company's Special Opinions on the Independence Assessment of Independent Directors in 2024" "Proposal on the Company's 2024 Profit Distribution Plan"

"Proposal on Submitting to the General Meeting of Shareholders to Authorize the Board of Directors to Pay Interim Dividends in 2025"

"Proposal on the implementation of the company's remuneration for directors and supervisors in 2024 and the remuneration plan for 2025"

"Proposal on the Company's 2024 Senior Management Remuneration Implementation and 2025 Remuneration Plan"

"Proposal on the Company's Special Report on the Deposit and Actual Use of Raised Funds in 2024"

"Proposal on the Company's 2024 Internal Control Evaluation Report"

"Proposal on the Re-appointment of the Company's Financial and Internal Control Audit Institution for 2025" "Proposal on the Company's Board of Directors Audit Committee's Report on the Accounting Firm's Performance of Supervisory Responsibilities in 2024"

"Proposal on the Company's 2024 Accounting Firm Performance Evaluation Report"

"Proposal on the Company's 2025 Action Plan of "Improving Quality, Increasing Efficiency and Focusing on Returns" "Proposal on Formulating the <Market Value Management System of Shanghai Ailes Medical Technology Co., Ltd.>"

"Proposal on Formulating the Public Opinion Management System of Shanghai Ailes Medical Technology Co., Ltd."

"Proposal on Proposing to Convene the Company's 2024 Annual General Meeting of Shareholders"

"Proposal on the Company's 2025 Semi-Annual Report and its Summary"

"Proposal on the Company's "10th Report of the Second Session of the Board of Directors on the Deposit and Actual Use of Funds Raised in the Half-Year 2025""

2025/8/25

five meetings

"Proposal on the Company's Profit Distribution Plan for the First Half of 2025"

"Proposal on the Company's Semi-annual Evaluation Report on the 2025 Action Plan of "Improving Quality, Increasing Efficiency and Focusing on Returns""

"Proposal on the Company's <2025 Third Quarter Report>"

"Proposal on canceling the Board of Supervisors, adjusting the seats on the Board of Directors and adding employee representative directors, and the tenth revision of the Articles of Association and related rules of procedure of the second session of the Board of Directors"

2025/10/27

six meetings

"Proposal on Amending and Establishing Part of the Company's Governance System"

"Proposal on the General Election of the Board of Directors and Nomination of Non-Independent Director Candidates for the Third Board of Directors"

"Proposal on the General Election of the Board of Directors and Nomination of Independent Director Candidates for the Third Board of Directors"

"Proposal on Convening the Company's First Extraordinary General Meeting of Shareholders in 2025" "Proposal on the Election of Chairman of the Company's Third Board of Directors"

"Proposal on the Election of Vice Chairman of the Company's Third Board of Directors"

First place in the third session of the Board of Directors

2025/11/27 "Proposal on the Election of Members of the Special Committees of the Third Board of Directors of the Company" meeting

"Proposal on Appointment of Senior Management of the Company"

"Proposal on the Appointment of the Company's Securities Affairs Representative"

The second of the third session of the Board of Directors

2025/12/15 "Proposal on Using Part of Temporarily Idle Raised Funds for Cash Management" meeting

(2) Implementation of the resolutions of the shareholders’ meeting by the board of directors

The company's board of directors strictly followed the authorization of the shareholders' meeting and conscientiously implemented various resolutions reviewed and approved by the shareholders' meeting. During the reporting period, the company held a total of 2 shareholders' meetings, the details of which are as follows:

Date Session Session Matters to be considered

"Proposal on the Company's <2024 Annual Report> and its Summary"

"Proposal on the Company's 2024 Board of Directors Work Report"

"Proposal on the Company's 2024 Supervisory Board Work Report"

"Proposal on the Company's 2024 Financial Final Accounts Report"

2024 Annual Shares "Proposal Regarding the Company's 2024 Independent Directors' Performance Report"

2025/5/14

East Assembly

"Proposal on the Company's Profit Distribution Plan for 2024"

"Proposal on Submitting to the General Meeting of Shareholders to Authorize the Board of Directors to Pay Interim Dividends for 2025" "Proposal on the Implementation of the Company's Directors and Supervisors' Remuneration in 2024 and the 2025 Remuneration Plan"

"Proposal on Re-appointment of the Company's Financial and Internal Control Audit Institution for 2025" "Proposal on Cancellation of the Board of Supervisors, Adjustment of Board of Directors Seats and Addition of Employee Representative Directors, Revision of the Company's Articles of Association and Related Rules of Procedure"

"Proposal on Amending and Establishing Part of the Company's Governance System"

"Proposal on the General Election of the Board of Directors and Nomination of Non-Independent Director Candidates for the Third Board of Directors"

The first "Proposal on the election of Mr. Du Jinhao as a non-independent director of the company's third board of directors 2025/11/27 Extraordinary General Meeting of Shareholders" in 2025

"Proposal on the election of Ms. Qi Ju as a non-independent director of the third session of the Company's Board of Directors" "Proposal on the election of Mr. Hu Jie as a non-independent director of the third session of the Company's Board of Directors" "Proposal on the election of Mr. Xu Feng as a non-independent director of the third session of the Company's Board of Directors" "Proposal on the election of Mr. Xu Cong as a non-independent director of the third session of the Company's Board of Directors"

"Proposal on the General Election of the Board of Directors and Nomination of Independent Director Candidates for the Third Board of Directors"

"Proposal on the election of Ms. Zhu Chafen as an independent director of the company's third board of directors" "Proposal on the election of Mr. Li Hanjie as an independent director of the company's third board of directors" "Proposal on the election of Mr. Li Chengzhang as an independent director of the company's third board of directors"

(3) Composition of special committees under the board of directors

The company's board of directors has four special committees, including: Audit Committee, Nomination Committee, Remuneration and Appraisal Committee, and Strategy and ESG Committee. Each special committee provides opinions or suggestions on professional matters in accordance with the implementation details of each special committee formulated by the company's board of directors for reference in decision-making by the board of directors.

Audit Committee

The audit committee of the company's second board of directors has three members, with director Yan Jun as the chairman; the audit committee of the third board of directors has three members, with director Zhu Chafen as the chairman. During the reporting period, the Audit Committee of the Company's Board of Directors, based on the principle of diligence and responsibility, carried out important tasks such as reviewing and expressing opinions on the Company's regular reports, appointment of audit institutions and other matters.

Nomination Committee

The Nomination Committee of the second session of the Board of Directors of the company has three members, with Director Lu Chao serving as the Chairman; the Nomination Committee of the third Board of Directors has three members, with Director Li Chengzhang serving as the Chairman. During the reporting period, members of the Nomination Committee performed their duties, further improved the company's governance structure, and standardized the selection and appointment procedures for the company's directors and senior managers.

Remuneration and Appraisal Committee

The company's second board of directors' remuneration and assessment committee has three members, with director Yang Jiayu serving as the chairman; the third board of directors' remuneration and assessment committee has three members, with director Li Hanjie serving as the chairman. The Remuneration and Appraisal Committee of the Board of Directors is a specialized working body established by the Board of Directors. It formulates and reviews the remuneration policies and plans for the company's directors and senior management personnel. It plays an important role in establishing and improving the evaluation and remuneration system for directors and senior management personnel and improving the company's evaluation and evaluation system.

Strategy and ESG Committee

The Strategy Committee of the second session of the company's board of directors has three members, with Chairman Du Jinhao serving as the chairman; the Strategy and ESG Committee (renamed) of the third session of the board of directors has three members, with chairman Du Jinhao serving as the chairman. During the reporting period, the Strategy and ESG Committee of the company's board of directors played an important role in enhancing the company's core competitiveness, strengthening the scientific nature of decision-making, and improving the efficiency and quality of major investment decisions.

(4) Composition of independent directors

The company's independent directors are established in accordance with relevant requirements such as the Articles of Association, Rules of Procedure of the Board of Directors, and Working System of Independent Directors. They must fully express their opinions based on their professional knowledge on major matters involving the company, provide a basis for the board of directors' scientific decision-making, and effectively safeguard the overall interests of the company and the interests of all shareholders, especially small and medium-sized shareholders. The company's second board of directors has four independent directors, including Yan Jun, Lu Chao, Yang Jiayu and Zhu Shengtao; the third board of directors has three independent directors, including Zhu Chafen, Li Hanjie and Li Chengzhang.

(5) Information disclosure work

During the reporting period, the company's board of directors strictly abided by the relevant regulations on information disclosure, completed regular report disclosures on time in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and fulfilled its information disclosure obligations in a truthful, accurate, complete and timely manner based on the company's actual situation to ensure that investors are informed of the company's major events in a timely manner and to protect the interests of investors to the greatest extent.

(6) Investor relations management work

During the reporting period, the company's Securities Affairs Department conscientiously managed the company's investor relations, coordinated information communication between the company and regulatory agencies, all shareholders, securities service agencies, media, etc., enhanced investors' understanding of the company, and promoted a positive interactive relationship between the company and investors.

(7) Statement of the Board of Directors on Internal Control Responsibilities

During the reporting period, the company's internal control-related systems have been formulated and implemented in accordance with relevant laws and regulations and the company's actual situation. In the future, the company will further improve the company's internal control to meet the company's current management requirements and company development needs, ensure the company's various business activities are carried out in an orderly manner, ensure the authenticity, accuracy and completeness of the company's financial reports and related accounting information, ensure the realization of the company's operation and management objectives, ensure that the company reports and discloses information in a true, accurate, complete, timely and fair manner, and effectively protects the interests of the company and all investors.

(8) Directors’ performance of duties, performance evaluation results and remuneration

During the reporting period, all directors of the company performed their duties diligently and diligently, actively performed their duties by attending the board of directors and shareholders' meetings, and were deeply integrated into the entire process of the company's operation and governance. The Remuneration and Appraisal Committee of the Board of Directors completes the performance evaluation of the company's directors in accordance with laws, regulations and the "Articles of Association" and "Remuneration Management System for Directors and Senior Management Personnel". For details on the directors' performance of duties and specific remuneration during the reporting period, please refer to the "2025 Annual Report" disclosed by the company.

3. Key points of the board of directors’ work plan in 2026

Looking back on 2025, the company will work together to build a culture and spirit of hard work and progress. This power drives all members of the company to move forward and successfully complete the annual business goals set by the company. Looking forward to the future, the board of directors will continue to embrace responsibility and original intention, use struggle as the pen and hard work as the ink, strive to write more outstanding operating results, return the trust and support of all shareholders, employees and partners, and actively fulfill social responsibilities with practical actions to contribute greater value to social development.

Proposal 2:

Proposal on the company’s profit distribution plan for 2025

Dear shareholders and shareholders’ agents:

The company's 2025 profit distribution plan is: The company plans to distribute profits in 2025 based on the total share capital registered on the equity registration date for implementing equity distribution. The company plans to distribute a cash dividend of RMB 6.00 (tax included) to all shareholders for every 10 shares. As of December 31, 2025, the company's total share capital is 450,000,000 shares, and based on this calculation, a total cash dividend of 270,000,000.00 yuan (including tax) is planned. The total amount of the company's cash dividends for this year (including cash dividends distributed in the interim period) is planned to be 450,000,000.00 yuan. The company will not issue bonus shares this year and will not convert capital reserve funds into share capital.

If the company's total share capital changes due to convertible bond conversion/share repurchase/share repurchase and cancellation of equity incentive grant shares/major asset restructuring and share repurchase and cancellation between the date of disclosure of relevant announcements on the profit distribution plan and the equity registration date for the implementation of equity distribution, the company plans to maintain the total distribution amount unchanged and adjust the per share distribution ratio accordingly.

The proposal has been reviewed and approved at the third meeting of the company's third board of directors and is now submitted to shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Proposal 3 of May 13, 2026:

Proposal to submit to the shareholders’ meeting to authorize the board of directors to pay interim dividends in 2026

Dear shareholders and shareholders’ agents:

In order to further enhance investor returns, in accordance with the "Regulatory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies", the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and other laws and regulations, as well as the relevant provisions of the "Articles of Association of Shanghai Alys Pharmaceutical Technology Co., Ltd." and based on the actual situation, the company may pay an interim dividend in 2026. The amount of dividends shall not exceed the net profit attributable to shareholders of the listed company during the corresponding period.

In order to simplify the dividend distribution procedure, the board of directors proposed that the 2025 Annual Shareholders Meeting authorize the board of directors to formulate a specific 2026 mid-term dividend plan subject to the conditions of profit distribution, and the board of directors and its authorized persons will specifically implement the relevant plan. The authorization period starts from the date of review and approval at the 2025 annual shareholders' meeting and ends on the date of the company's 2026 annual shareholders' meeting.

The proposal has been reviewed and approved at the third meeting of the company's third board of directors and is now submitted to shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Resolution 4 of May 13, 2026:

Regarding the company’s implementation of directors’ remuneration in 2025

and the proposal for the 2026 remuneration package

Dear shareholders and shareholders’ agents:

In order to fully mobilize the enthusiasm of the company's directors and promote the company's standardized, steady and orderly development, combined with the company's actual situation, the company's 2025 director remuneration implementation and 2026 remuneration plan are confirmed as follows:

1. Remuneration payment situation of non-independent directors in 2025

Unit: RMB 10,000 yuan

Name Position Total pre-tax remuneration received from the company in 2025 Du Jinhao Chairman 497.61 Hu Jie Vice Chairman 304.57 Qi Ju Director 102.40 Xu Feng Director 282.80 Xu Cong Director 0.00 Chu Shengming Employee Representative Director (newly appointed in 2025) 5.07 JEFFREYYANGGUO Director (resigns within 2025) 0.00 Xie Ronggang Director (resigns within 2025) 0.00 Note 1: According to calculations by the Human Resources Department, the "total pre-tax remuneration received from the company in 2025" does not include share-based payment expenses corresponding to equity incentives that the company has implemented.

Note 2: Directors Du Jinhao, Hu Jie and Xu Feng, who are also senior managers, receive corresponding remuneration based on their specific positions in the company and will not receive additional director remuneration or allowances.

2. Remuneration payment situation of independent directors in 2025

Unit: RMB 10,000

Name Position Total pre-tax remuneration received from the company in 2025 Zhu Chafen Independent Director (newly appointed within 2025) 1.09 Li Hanjie Independent Director (newly appointed within 2025) 1.09 Li Chengzhang Independent Director (newly appointed within 2025) 1.09 Yang Jiayu Independent Director (resigned within 2025) 8.73 Lu Chao Independent Director (resigns within 2025) 8.73 Yan Jun Independent Director (resigns within 2025) 8.73 Zhu Shengtao Independent Director (resigns within 2025) 8.73 Note: According to calculations by the Human Resources Department, the "total pre-tax remuneration received from the company in 2025" refers to the allowances received while serving as the company's independent director.

3. Salary plan for 2026

In accordance with the company's "Remuneration Management System for Directors and Senior Management Personnel" and other relevant regulations, combined with the company's actual operating and development conditions and with reference to industry salary levels and other factors, the company's 2026 director remuneration plan is formulated as follows:

Scope of application

Directors of the company for the 2026 term.

Applicable period

From January 1, 2026 to December 31, 2026.

Salary plan

(1) Non-independent directors

a. Internal directors who hold specific positions in the company will receive corresponding remuneration based on the specific positions they hold in the company (the proportion of performance remuneration shall in principle be no less than 50% of the total basic remuneration and performance remuneration) and will not receive additional director remuneration or allowances.

b. For outside directors who do not hold specific positions in the company, the amount of service allowance shall be recommended by the Remuneration and Appraisal Committee. (2) Independent directors

The allowance for independent directors is RMB 120,000 per year before tax and is paid monthly. Independent directors do not participate in the company's internal performance evaluation linked to remuneration.

Stop payment recourse mechanism

When the financial report is restated retrospectively due to financial fraud or other misstatements, the company will promptly reassess the directors' performance compensation and medium- and long-term incentive income and recover the excess payment accordingly.

If a director violates his obligations and causes losses to the company, or is at fault for illegal activities such as financial fraud, misappropriation of funds, illegal guarantees, etc., the company will reduce or stop paying unpaid performance remuneration and medium- and long-term incentive income according to the severity of the case, and fully or partially recover the performance remuneration and medium- and long-term incentive income that have been paid during the period when the relevant behavior occurred. The proposal has been reviewed by the Remuneration and Assessment Committee of the company's board of directors. Because it involves members' remuneration, based on the principle of prudence, all members abstained from voting and were directly submitted to the company's board of directors for review. This proposal involves the remuneration of all directors. Based on the principle of prudence, all directors of this proposal abstained from voting and were directly submitted to the company's shareholders' meeting for review. It is now submitted to all shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Proposal 5 of May 13, 2026:

Regarding the revision of "Directors and Senior Management Personnel of Shanghai Ailes Pharmaceutical Technology Co., Ltd."

Proposal on "Remuneration Management System"

Dear shareholders and shareholders’ agents:

In order to further improve the salary and allowance management of the company's directors and senior managers, establish a scientific and effective incentive and restraint mechanism, and effectively mobilize the work enthusiasm of the company's directors and senior managers, in accordance with the "Company Law", "Code of Governance of Listed Companies", "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and other relevant laws, regulations, rules and normative documents and the "Articles of Association", the company plans to revise the "Remuneration Management System for Directors and Senior Management Personnel". For details of the revised system, please refer to the "Remuneration Management System for Directors and Senior Management Personnel of Shanghai Ailes Medical Technology Co., Ltd." published by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 23, 2026.

The proposal has been reviewed by the Remuneration and Assessment Committee of the company's board of directors. Based on the principle of prudence, all members abstained from voting and were directly submitted to the company's board of directors for review. Based on the principle of prudence, all directors of the proposal abstained from voting and were directly submitted to the company's shareholders' meeting for review. It is now submitted to all shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Resolution 6 of May 13, 2026:

Proposal on Re-appointing the Company’s Financial and Internal Control Audit Institution for 2026

Dear shareholders and shareholders’ agents:

In view that the term of Ernst & Young Hua Ming LLP as the auditor for 2025 has expired, in order to ensure the continuity of the company's audit work, it is planned to continue to engage Ernst & Young Hua Ming LLP (Special General Partnership) as the company's financial and internal control auditor for 2026. , for specific content, please refer to the "Announcement of Shanghai Ellis Medical Technology Co., Ltd. on the Re-appointment of the Company's Financial and Internal Control Audit Agency for 2026" published by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on April 23, 2026.

The proposal has been reviewed and approved by the audit committee of the company's board of directors and the third meeting of the third board of directors, and is now submitted to shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Proposal 7 of May 13, 2026:

Proposal on purchasing Dong Gao liability insurance

Dear shareholders and shareholders’ agents:

In order to further improve the company's risk management system, reduce the company's operational risks, and at the same time promote the company's directors and senior managers to fully exercise their rights, perform their duties and obligations, and protect the interests of investors, in accordance with the "Company Law of the People's Republic of China", "Listed Company Governance Code" and other relevant regulations, the company plans to purchase liability insurance (hereinafter referred to as "Dong Gao Liability Insurance") for the company, all directors, senior managers and relevant responsible personnel. The basic situation of the plan is as follows:

1. Insured person: Shanghai Alice Medical Technology Co., Ltd.

Insured: the company and all directors, senior managers and relevant responsible personnel (specifically, the final signed insurance contract shall prevail)
Compensation limit: no more than RMB 100 million (specifically subject to the final signed insurance contract)
Insurance premium budget: no more than RMB 300,000 (specifically subject to the final signed insurance contract)

5. Insurance period: 1 year (can be renewed or re-insured every year)

In order to improve the efficiency of decision-making, the company's board of directors intends to request the shareholders' meeting to authorize the company's management to handle matters related to the purchase of liability insurance for directors, senior managers and other responsible personnel (including but not limited to determining the insurance company, insurance amount, insurance premium and other insurance terms; selecting and engaging insurance brokers and other intermediaries, signing relevant legal documents and handling other matters related to insurance, etc.), as well as handling matters related to renewal or re-insurance at or before the expiration of the Donggao liability insurance contract in the future. Renewal or re-insurance is within the scope of the above-mentioned insurance plans, and there is no need to perform relevant decision-making procedures separately. The authorization is valid until the end of the term of the third board of directors and does not affect the validity of the insurance contracts signed at that time.

This proposal has been withdrawn from the vote by all directors of the company's board of directors and has been directly submitted to the company's shareholders' meeting for review. It is now submitted to all shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Resolution 8 of May 13, 2026:

Regarding the completion of some fundraising projects and the remaining raised funds

Proposal for new drug research and development projects and supplementary working capital

Dear shareholders and shareholders’ agents:

In view of the fact that the company's investment project with raised funds, "an additional annual output of 150 million tablets of fumetinib mesylate solid preparation production project" has passed the drug GMP compliance inspection and has reached the intended usable status, the company plans to close the above-mentioned investment project with raised funds. Among them, the remaining raised funds of 11.6809 million yuan will be used for the "new drug research and development project", and the remaining interest and net financial income will be 10.2811 million yuan is used to supplement working capital. The actual amount transferred out shall be the amount calculated on the day when the funds are transferred out. For details, please refer to the "Announcement of Shanghai Ellis Medical Technology Co., Ltd. on the Closing of Part of the Raised Investment Projects and the Use of the Surplus Raised Funds for New Drug Research and Development Projects, Supplementing Working Capital, and Adjusting New Drug Research and Development Projects" published by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 23, 2026.

The proposal has been reviewed and approved at the third meeting of the company's third board of directors and is now submitted to shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Proposal 9 of May 13, 2026:

Proposal on adjusting new drug research and development projects

Dear shareholders and shareholders’ agents:

As the company's ongoing research projects continue to advance, the company plans to adjust the investment amount of some sub-projects of the "new drug research and development project" and use the remaining 11.6809 million yuan raised from the company's original "new annual output of 150 million tablets of fumetinib mesylate solid preparation production project" to make additional investment in the "new drug research and development project". For details, please refer to the "Announcement of Shanghai Ailes Medical Technology Co., Ltd. on the Closing of Part of the Raised Investment Projects and the Use of the Surplus Raised Funds for New Drug Research and Development Projects, Supplementing Working Capital, and Adjusting New Drug Research and Development Projects" published by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 23, 2026.

The proposal has been reviewed and approved at the third meeting of the company's third board of directors and is now submitted to shareholders and shareholders' agents for review.

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

Matters heard on May 13, 2026:

2025 Independent Directors’ Work Report

(Zhu Chafen, Li Hanjie, Li Chengzhang, Yan Jun, Yang Jiayu, Lu Chao, Zhu Shengtao) Dear shareholders and shareholders’ agents:

The independent directors will now report to you the "2025 Independent Directors' Work Report". For details of the 2025 performance report of the company's independent directors, please refer to the "2025 performance report of the independent directors of Shanghai Ellis Medical Technology Co., Ltd." published by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 23, 2026 (Zhu Chafen, Li Hanjie, Li Chengzhang, Yan Jun, Yang Jiayu, Lu Chao, Zhu Shengtao).

Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

May 13, 2026

2026 annual compensation package for senior management of the company

Dear shareholders and shareholders’ agents:

In accordance with relevant regulations such as the "Remuneration Management System for Directors and Senior Managers of the Company", combined with the actual operation and development of the company and with reference to industry salary levels and other factors, the company's 2026 senior management salary plan is formulated as follows:

1. Scope of application

The company's senior executives will serve through 2026.

2. Applicable period

From January 1, 2026 to December 31, 2026.

3. Salary plan

The total remuneration of the company’s senior management personnel consists of basic salary and performance remuneration (the proportion of performance remuneration shall in principle be no less than 50% of the total basic remuneration and performance remuneration).
Basic salary is determined comprehensively based on industry salary levels, personal job responsibilities, work experience and other factors, and is paid on a monthly basis.
Performance remuneration is based on performance appraisal. Annual performance remuneration is linked to the achievement of the company's annual operating goals and is determined based on assessment indicators and actual completion. Performance remuneration, which accounts for a certain proportion of the total annual performance remuneration, is paid after the disclosure of the company's annual report and performance evaluation.
Stop payment recourse mechanism

When the financial report is restated retrospectively due to financial fraud or other misstatements, the company will promptly re-evaluate the performance compensation and mid- and long-term incentive income of senior managers and recover the excess payment accordingly.

If senior managers breach their obligations and cause losses to the company, or are at fault for financial fraud, misappropriation of funds, illegal guarantees and other illegal activities, the company will reduce or stop paying unpaid performance remuneration and medium- and long-term incentive income according to the severity of the case, and fully or partially recover the performance remuneration and medium- and long-term incentive income that have been paid during the period when the relevant behavior occurred.

The proposal involved in this matter has been reviewed and approved by the Remuneration and Assessment Committee of the company's board of directors, and member Du Jinhao abstained from voting. The proposal has been reviewed and approved at the third meeting of the company's third board of directors. Directors Du Jinhao, Hu Jie and Xu Feng, who are also senior managers, and related director Qi Ju abstained from voting. All shareholders and shareholders' agents are hereby invited to listen. Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.

May 13, 2026